longer subject to

Form 5 obligations may continue. See

Instruction 1(b).

Section 16. Form 4 or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL OMB 3235-Number: 0287 Estimated average burden hours per response...

Stock

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Respons	es)													
1. Name and Address of Reporting Person * Saks Samuel R			Symbol	Tonix Pharmaceuticals Holding Con					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner Officer(give title Other (specify below)						
HOLDIN	(Fin NIX PHAR NG CORP., E, SUITE	,	3. Date of Earliest Transaction (Month/Day/Year) 06/17/2014												
NEW YO	ORK, NY 1		4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person							
(City)	(Sta	ate) (Zip)	Table I - N	on-Deriv	vativ	e Securi	ities	Acquired, l	Disposed of, o	r Beneficia	lly Owne	d			
1.Title of S (Instr. 3)	D	Date Ex Month/Day/Year) an	y Ionth/Day/Year) C (I	ransactio ode instr. 8)	n A D (I		(A) of (I 4 and (A) or	or Secu D) Bene d 5) Follo Trans (Instr	mount of rities ficially Owned wing Reported saction(s) r. 3 and 4)	l Form:	ect (Instr	direct ficial ership			
Reminder: directly or	*	separate line for each	class of securities		Persinfor	sons wl rmatior uired to	res	ntained in spond unle	the collection this form are ss the form are trol number.	e not		C 1474 (9-02)			
			ivative Securities	-		-	-		•						
1. Title of 2. 3. Transaction 3A Derivative Conversion Date Executity or Exercise (Month/Day/Year) an		3A. Deemed Execution Date, if any	ecution Date, if Transaction			ber	5. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock	\$ 9.87	06/17/2014		A		5,000		(1)	06/17/2024	Common	5,000	\$ 0 (2)	5,000	D	

Reporting Owners

Option

Barandina Orana Nama / Adduna	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
Saks Samuel R C/O TONIX PHARMACEUTICALS HOLDING CORP. 509 MADISON AVENUE, SUITE 306 NEW YORK, NY 10022	X						

Signatures

/s/ Samuel Saks	06/23/2014
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- $\textbf{(1)} \ The \ option \ vests \ 1/3rd \ on \ the \ first \ anniversary \ of \ issuance \ and \ 1/36th \ each \ month \ thereafter \ for \ 24 \ months.$
- (2) The option was granted pursuant to the Issuer's 2014 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.